Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
DexCom Inc., historical price multiples (quarterly data)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | DexCom Inc. P/E ratio decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | DexCom Inc. P/OP ratio decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | DexCom Inc. P/S ratio decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | DexCom Inc. P/BV ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023. |
Price to Earnings (P/E)
DexCom Inc., historical P/E calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 386,373,935 | 387,871,796 | 387,635,623 | 386,413,690 | 386,258,125 | 392,581,776 | 392,503,732 | 388,262,536 | 387,688,136 | 386,995,604 | 386,823,492 | 384,709,452 | 384,110,412 | 382,968,828 | 369,379,512 | 366,376,568 | 366,114,352 | 364,743,956 | 364,201,620 | 360,007,068 | 355,377,380 | 353,422,932 | 352,339,732 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Net income (loss) (in thousands) | 120,700) | 115,900) | 48,600) | 91,800) | 101,200) | 50,900) | 97,300) | (19,400) | 70,900) | 62,900) | 40,300) | 355,200) | 72,200) | 46,300) | 19,900) | 92,700) | 45,800) | (10,500) | (26,900) | (179,700) | 46,600) | 30,200) | (24,200) | |||||||
| Earnings per share (EPS)2 | 0.98 | 0.92 | 0.75 | 0.88 | 0.60 | 0.51 | 0.54 | 0.40 | 1.37 | 1.37 | 1.33 | 1.28 | 0.60 | 0.53 | 0.40 | 0.28 | -0.47 | -0.47 | -0.36 | -0.35 | 0.00 | 0.00 | 0.00 | |||||||
| Share price1, 3 | 81.09 | 129.36 | 123.58 | 107.24 | 101.25 | 86.99 | 103.31 | 101.75 | 142.58 | 114.01 | 105.43 | 102.55 | 95.16 | 104.45 | 78.38 | 63.05 | 38.28 | 39.22 | 29.66 | 36.56 | 33.23 | 23.86 | 18.58 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/E ratio4 | 83.11 | 140.35 | 163.77 | 121.45 | 170.04 | 171.01 | 191.54 | 255.37 | 104.43 | 83.15 | 79.34 | 79.93 | 158.17 | 195.41 | 195.75 | 228.49 | — | — | — | — | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/E Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 31.95 | 36.16 | 33.21 | 26.76 | 21.95 | 22.24 | 25.48 | 29.13 | 31.42 | 33.80 | 36.79 | 48.49 | 58.45 | 58.36 | 45.61 | 41.83 | — | — | — | — | — | — | — | |||||||
| Cigna Group | 17.59 | 12.80 | 11.43 | 13.13 | 14.99 | 15.60 | 15.72 | 13.43 | 8.43 | 8.60 | 10.62 | 8.71 | 14.60 | 12.08 | 13.82 | 13.26 | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 10.28 | 33.58 | 22.61 | 27.53 | 40.34 | 16.30 | 16.49 | 17.39 | 16.78 | 14.94 | 14.44 | 12.88 | 10.69 | 10.20 | 10.94 | 14.15 | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 18.14 | 17.03 | 17.46 | 19.20 | 18.75 | 18.07 | 20.46 | 18.13 | 18.65 | 22.10 | 19.99 | 15.87 | 14.35 | 11.97 | 14.80 | 15.96 | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 19.98 | 17.74 | 20.27 | 22.52 | 25.24 | 19.26 | 18.48 | 18.34 | 22.09 | 22.82 | 15.20 | 14.48 | 13.49 | 15.26 | 19.09 | 18.10 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 61.96 | 79.78 | 79.43 | 64.99 | 56.03 | 52.74 | 55.10 | 59.94 | 71.86 | 69.15 | 89.95 | 87.47 | 82.17 | 70.73 | 44.27 | 48.72 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 26.88 | 24.40 | 22.61 | 23.38 | 29.39 | 30.66 | 46.71 | 46.56 | 55.13 | 42.80 | 32.34 | 26.30 | 25.38 | 31.86 | 32.75 | 28.78 | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | 22.75 | 22.15 | 22.01 | 22.46 | 26.13 | 27.70 | 27.29 | 26.03 | 27.92 | 27.41 | 23.06 | 20.54 | 17.70 | 16.88 | 19.91 | 20.48 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
EPS
= (Net income (loss)Q3 2023
+ Net income (loss)Q2 2023
+ Net income (loss)Q1 2023
+ Net income (loss)Q4 2022)
÷ No. shares of common stock outstanding
= (120,700,000 + 115,900,000 + 48,600,000 + 91,800,000)
÷ 386,373,935 = 0.98
3 Closing price as at the filing date of DexCom Inc. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/E ratio = Share price ÷ EPS
= 81.09 ÷ 0.98 = 83.11
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | DexCom Inc. P/E ratio decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Price to Operating Profit (P/OP)
DexCom Inc., historical P/OP calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 386,373,935 | 387,871,796 | 387,635,623 | 386,413,690 | 386,258,125 | 392,581,776 | 392,503,732 | 388,262,536 | 387,688,136 | 386,995,604 | 386,823,492 | 384,709,452 | 384,110,412 | 382,968,828 | 369,379,512 | 366,376,568 | 366,114,352 | 364,743,956 | 364,201,620 | 360,007,068 | 355,377,380 | 353,422,932 | 352,339,732 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Operating income (loss) (in thousands) | 205,500) | 128,100) | 47,200) | 125,400) | 147,500) | 77,000) | 41,300) | 600) | 118,300) | 101,000) | 45,900) | 104,000) | 94,100) | 67,800) | 33,600) | 101,500) | 56,000) | (800) | (14,400) | (164,600) | 13,900) | (4,900) | (30,700) | |||||||
| Operating profit per share2 | 1.31 | 1.16 | 1.02 | 1.01 | 0.69 | 0.60 | 0.67 | 0.68 | 0.95 | 0.89 | 0.81 | 0.78 | 0.77 | 0.68 | 0.52 | 0.39 | -0.34 | -0.45 | -0.47 | -0.52 | 0.00 | 0.00 | 0.00 | |||||||
| Share price1, 3 | 81.09 | 129.36 | 123.58 | 107.24 | 101.25 | 86.99 | 103.31 | 101.75 | 142.58 | 114.01 | 105.43 | 102.55 | 95.16 | 104.45 | 78.38 | 63.05 | 38.28 | 39.22 | 29.66 | 36.56 | 33.23 | 23.86 | 18.58 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/OP ratio4 | 61.89 | 111.95 | 120.63 | 105.93 | 146.80 | 143.97 | 155.24 | 148.63 | 149.72 | 127.89 | 130.80 | 131.73 | 123.07 | 154.50 | 152.14 | 162.33 | — | — | — | — | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 27.48 | 30.47 | 27.70 | 22.18 | 18.35 | 18.63 | 21.33 | 24.45 | 26.84 | 29.01 | 31.39 | 40.69 | 45.82 | 45.19 | 35.87 | 34.03 | — | — | — | — | — | — | — | |||||||
| Cigna Group | 11.38 | 10.51 | 9.34 | 10.40 | 12.05 | 10.20 | 10.40 | 9.08 | 9.12 | 9.28 | 11.13 | 9.03 | 9.24 | 7.58 | 8.59 | 8.38 | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 6.32 | 15.41 | 11.67 | 14.75 | 20.01 | 9.97 | 10.06 | 10.43 | 9.43 | 7.87 | 7.61 | 6.65 | 5.89 | 5.98 | 6.19 | 7.83 | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 14.38 | 13.36 | 13.61 | 15.05 | 15.30 | 14.72 | 17.53 | 15.70 | 15.81 | 19.93 | 15.79 | 12.10 | 10.93 | 9.03 | 11.95 | 13.55 | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 13.43 | 13.47 | 14.93 | 16.63 | 18.96 | 18.96 | 17.45 | 17.08 | 21.55 | 14.39 | 11.02 | 9.78 | 9.84 | 11.28 | 14.59 | 15.35 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 55.63 | 70.08 | 66.95 | 54.49 | 46.65 | 44.54 | 49.98 | 56.11 | 67.95 | 69.51 | 89.18 | 88.37 | 83.88 | 71.30 | 43.68 | 48.89 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 19.53 | 17.99 | 19.55 | 20.48 | 25.40 | 27.20 | 38.83 | 37.44 | 49.88 | 42.55 | 35.86 | 26.29 | 21.01 | 23.52 | 22.21 | 21.26 | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | 15.63 | 15.33 | 15.41 | 15.89 | 18.75 | 19.96 | 19.69 | 18.77 | 19.63 | 19.05 | 16.12 | 14.12 | 12.35 | 11.85 | 13.80 | 14.40 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
Operating profit per share
= (Operating income (loss)Q3 2023
+ Operating income (loss)Q2 2023
+ Operating income (loss)Q1 2023
+ Operating income (loss)Q4 2022)
÷ No. shares of common stock outstanding
= (205,500,000 + 128,100,000 + 47,200,000 + 125,400,000)
÷ 386,373,935 = 1.31
3 Closing price as at the filing date of DexCom Inc. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 81.09 ÷ 1.31 = 61.89
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | DexCom Inc. P/OP ratio decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Price to Sales (P/S)
DexCom Inc., historical P/S calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 386,373,935 | 387,871,796 | 387,635,623 | 386,413,690 | 386,258,125 | 392,581,776 | 392,503,732 | 388,262,536 | 387,688,136 | 386,995,604 | 386,823,492 | 384,709,452 | 384,110,412 | 382,968,828 | 369,379,512 | 366,376,568 | 366,114,352 | 364,743,956 | 364,201,620 | 360,007,068 | 355,377,380 | 353,422,932 | 352,339,732 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Revenue (in thousands) | 975,000) | 871,300) | 741,500) | 815,200) | 769,600) | 696,200) | 628,800) | 698,200) | 650,200) | 595,100) | 505,000) | 568,900) | 500,900) | 451,800) | 405,100) | 462,800) | 396,300) | 336,400) | 280,500) | 338,000) | 266,700) | 242,500) | 184,400) | |||||||
| Sales per share2 | 8.81 | 8.24 | 7.80 | 7.53 | 7.23 | 6.81 | 6.55 | 6.31 | 5.98 | 5.61 | 5.24 | 5.01 | 4.74 | 4.48 | 4.33 | 4.03 | 3.69 | 3.35 | 3.10 | 2.87 | 0.00 | 0.00 | 0.00 | |||||||
| Share price1, 3 | 81.09 | 129.36 | 123.58 | 107.24 | 101.25 | 86.99 | 103.31 | 101.75 | 142.58 | 114.01 | 105.43 | 102.55 | 95.16 | 104.45 | 78.38 | 63.05 | 38.28 | 39.22 | 29.66 | 36.56 | 33.23 | 23.86 | 18.58 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/S ratio4 | 9.21 | 15.69 | 15.85 | 14.24 | 14.00 | 12.77 | 15.76 | 16.13 | 23.83 | 20.33 | 20.12 | 20.48 | 20.08 | 23.31 | 18.09 | 15.65 | 10.37 | 11.71 | 9.58 | 12.76 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/S Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 4.13 | 4.64 | 4.64 | 4.25 | 3.85 | 4.18 | 4.42 | 4.78 | 5.38 | 5.36 | 5.64 | 6.30 | 6.13 | 5.77 | 5.09 | 4.83 | — | — | — | — | — | — | — | |||||||
| Cigna Group | 0.49 | 0.46 | 0.42 | 0.49 | 0.55 | 0.48 | 0.48 | 0.42 | 0.42 | 0.42 | 0.55 | 0.46 | 0.50 | 0.41 | 0.45 | 0.44 | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 0.26 | 0.29 | 0.27 | 0.36 | 0.40 | 0.43 | 0.44 | 0.47 | 0.45 | 0.39 | 0.40 | 0.35 | 0.32 | 0.32 | 0.30 | 0.37 | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 0.66 | 0.66 | 0.68 | 0.74 | 0.77 | 0.75 | 0.89 | 0.81 | 0.78 | 0.73 | 0.76 | 0.60 | 0.61 | 0.63 | 0.65 | 0.74 | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 0.59 | 0.61 | 0.66 | 0.68 | 0.78 | 0.68 | 0.65 | 0.65 | 0.73 | 0.71 | 0.73 | 0.64 | 0.76 | 0.76 | 0.74 | 0.76 | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 13.72 | 17.06 | 16.21 | 13.81 | 12.62 | 12.69 | 15.34 | 17.89 | 22.12 | 21.73 | 23.19 | 21.29 | 20.09 | 18.44 | 13.33 | 15.01 | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 3.55 | 3.42 | 3.79 | 3.72 | 4.54 | 4.54 | 5.74 | 5.57 | 5.71 | 5.43 | 5.11 | 4.36 | 4.34 | 4.82 | 4.72 | 4.36 | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | 1.39 | 1.35 | 1.37 | 1.40 | 1.62 | 1.66 | 1.61 | 1.58 | 1.55 | 1.47 | 1.49 | 1.24 | 1.18 | 1.17 | 1.12 | 1.18 | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
Sales per share
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ No. shares of common stock outstanding
= (975,000,000 + 871,300,000 + 741,500,000 + 815,200,000)
÷ 386,373,935 = 8.81
3 Closing price as at the filing date of DexCom Inc. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/S ratio = Share price ÷ Sales per share
= 81.09 ÷ 8.81 = 9.21
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | DexCom Inc. P/S ratio decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Price to Book Value (P/BV)
DexCom Inc., historical P/BV calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 386,373,935 | 387,871,796 | 387,635,623 | 386,413,690 | 386,258,125 | 392,581,776 | 392,503,732 | 388,262,536 | 387,688,136 | 386,995,604 | 386,823,492 | 384,709,452 | 384,110,412 | 382,968,828 | 369,379,512 | 366,376,568 | 366,114,352 | 364,743,956 | 364,201,620 | 360,007,068 | 355,377,380 | 353,422,932 | 352,339,732 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
| Stockholders’ equity (in thousands) | 2,267,900) | 2,100,400) | 2,233,000) | 2,131,800) | 1,824,500) | 2,255,900) | 2,189,300) | 2,251,500) | 2,136,100) | 1,997,600) | 1,903,200) | 1,826,500) | 1,499,300) | 1,353,900) | 934,500) | 882,600) | 764,300) | 688,300) | 668,600) | 663,300) | 562,200) | 482,100) | 421,700) | |||||||
| Book value per share (BVPS)2 | 5.87 | 5.42 | 5.76 | 5.52 | 4.72 | 5.75 | 5.58 | 5.80 | 5.51 | 5.16 | 4.92 | 4.75 | 3.90 | 3.54 | 2.53 | 2.41 | 2.09 | 1.89 | 1.84 | 1.84 | 1.58 | 1.36 | 1.20 | |||||||
| Share price1, 3 | 81.09 | 129.36 | 123.58 | 107.24 | 101.25 | 86.99 | 103.31 | 101.75 | 142.58 | 114.01 | 105.43 | 102.55 | 95.16 | 104.45 | 78.38 | 63.05 | 38.28 | 39.22 | 29.66 | 36.56 | 33.23 | 23.86 | 18.58 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||||
| P/BV ratio4 | 13.82 | 23.89 | 21.45 | 19.44 | 21.44 | 15.14 | 18.52 | 17.55 | 25.88 | 22.09 | 21.43 | 21.60 | 24.38 | 29.55 | 30.98 | 26.17 | 18.34 | 20.78 | 16.16 | 19.84 | 21.01 | 17.49 | 15.52 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | 4.40 | 5.02 | 5.21 | 5.06 | 4.85 | 5.21 | 5.56 | 5.75 | 6.61 | 6.38 | 6.27 | 6.65 | 6.30 | 5.94 | 5.40 | 4.96 | 4.65 | 4.86 | 4.49 | — | — | — | — | |||||||
| Cigna Group | 2.04 | 1.87 | 1.73 | 1.95 | 2.20 | 1.86 | 1.84 | 1.53 | 1.49 | 1.44 | 1.86 | 1.46 | 1.61 | 1.34 | 1.51 | 1.49 | 1.49 | 1.44 | 1.42 | — | — | — | — | |||||||
| CVS Health Corp. | 1.19 | 1.35 | 1.26 | 1.61 | 1.80 | 1.77 | 1.79 | 1.83 | 1.71 | 1.47 | 1.51 | 1.33 | 1.24 | 1.24 | 1.21 | 1.47 | 1.47 | 1.23 | 1.25 | — | — | — | — | |||||||
| Elevance Health Inc. | 2.87 | 2.86 | 2.90 | 3.19 | 3.24 | 3.08 | 3.55 | 3.07 | 2.88 | 2.67 | 2.78 | 2.19 | 2.10 | 2.06 | 2.23 | 2.42 | 2.13 | 2.40 | 2.15 | — | — | — | — | |||||||
| Humana Inc. | 3.55 | 3.56 | 3.81 | 4.13 | 4.36 | 3.91 | 3.66 | 3.34 | 3.63 | 3.82 | 3.99 | 3.55 | 3.55 | 3.71 | 4.04 | 4.07 | 3.48 | 3.38 | 3.07 | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 7.49 | 9.57 | 9.29 | 7.78 | 6.71 | 6.29 | 7.48 | 8.59 | 10.64 | 10.35 | 10.40 | 9.53 | 9.35 | 9.19 | 7.22 | 8.13 | 8.43 | 8.49 | 8.68 | — | — | — | — | |||||||
| Medtronic PLC | 2.12 | 2.03 | 2.23 | 2.24 | 2.75 | 2.77 | 3.52 | 3.26 | 3.14 | 3.02 | 2.84 | 2.48 | 2.60 | 2.94 | 2.87 | 2.66 | 2.48 | 2.62 | 2.59 | — | — | — | — | |||||||
| UnitedHealth Group Inc. | 5.84 | 5.68 | 5.60 | 5.81 | 6.80 | 6.94 | 6.54 | 6.27 | 6.13 | 5.76 | 5.86 | 4.83 | 4.54 | 4.53 | 4.81 | 4.92 | 4.32 | 4.40 | 4.37 | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 2,267,900,000 ÷ 386,373,935 = 5.87
3 Closing price as at the filing date of DexCom Inc. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/BV ratio = Share price ÷ BVPS
= 81.09 ÷ 5.87 = 13.82
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | DexCom Inc. P/BV ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023. |